CPC
AVEO

Cookson Peirce & Co’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Cookson Peirce & Co’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,000
Closed -$99K – 231
2022
Q3 		$99K Buy
+12,000
New +$92.2K 0.01% 181

Other funds holding AVEO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Cookson Peirce & Co's AVEO Position: Q4 2022 in Review

Cookson Peirce & Co sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 12,000 shares — an estimated $99K sold.

Cookson Peirce & Co first reported a position in AVEO in Q3 2022 and held it in 1 quarter. The position peaked at $99K in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • Cookson Peirce & Co reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Cookson Peirce & Co sold 12,000 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $99K.
  • Cookson Peirce & Co first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Cookson Peirce & Co's AVEO Pharmaceuticals, Inc. position peaked at $99K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on Cookson Peirce & Co's 13F filing for Q4 2022, filed 31 Jan 2023.